Immunic News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.11.24	EQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology (EQS Group)
07.11.24	EQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update (EQS Group)
31.10.24	EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (EQS Group)
29.10.24	EQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in November (EQS Group)
22.10.24	Immunic Announces Positive Outcome From Interim Futility Analysis Of Phase 3 ENSURE Program (RTTNews)
22.10.24	EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis (EQS Group)
18.09.24	EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis (EQS Group)
04.09.24	EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome (EQS Group)
28.08.24	EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September (EQS Group)
08.08.24	EQS-News: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update (EQS Group)
01.08.24	EQS-News: Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update (EQS Group)
24.07.24	EQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (EQS Group)
05.01.24	Immunicto Privately Place Up To $240 Mln Of Shares; Stock Up In Pre-market (RTTNews)
21.11.23	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis (PR Newswire)
02.11.23	Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts (PR Newswire)
26.10.23	Immunic to Participate in Scientific and Industry Conferences in November (PR Newswire)
16.10.23	Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 (PR Newswire)
15.10.23	Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 (PR Newswire)
11.10.23	Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting (PR Newswire)
10.10.23	Immunic Announces Positive Interim Data From Multiple Sclerosis Trial; Stock Surges (RTTNews)
09.10.23	Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
04.10.23	Immunic to Participate in Scientific Conferences in October (PR Newswire)
06.09.23	Immunic to Participate in Industry and Investor Conferences in September (PR Newswire)
17.08.23	Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
01.08.23	Immunic to Participate in Investor and Scientific Conferences in August (PR Newswire)
27.07.23	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update (PR Newswire)
29.06.23	Immunic to Participate in Scientific and Investor Conferences in July (PR Newswire)
30.05.23	Immunic to Participate in Scientific and Investor Conferences in June (PR Newswire)
17.05.23	Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis (PR Newswire)
09.05.23	Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update (PR Newswire)
06.05.23	Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action (PR Newswire)
04.05.23	Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders (PR Newswire)
27.04.23	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. (PR Newswire)
26.04.23	Immunic to Participate in Investor and Scientific Conferences in May (PR Newswire)
05.04.23	Immunic Announces Positive Data From Maintenance Phase Of CALDOSE-1 Study Of Vidofludimus Calcium UC (RTTNews)
05.04.23	Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis (PR Newswire)
02.03.23	Immunic to Participate in Investor and Scientific Conferences in March (PR Newswire)
22.02.23	Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 (PR Newswire)
16.02.23	Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update (PR Newswire)
09.02.23	Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need (PR Newswire)
25.01.23	Immunic to Participate in Scientific and Investor Conferences in February (PR Newswire)
17.11.22	Immunic : Data Show Encouraging Signals For Vidofludimus Calcium For Delaying Disability Worsening (RTTNews)
17.11.22	Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential (PR Newswire)
10.11.22	Immunic to Participate in Investor and Scientific Conferences in November and December (PR Newswire)
27.10.22	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update (PR Newswire)
21.10.22	Pre-market Movers: IMUX, ARC, SNAP, VRE, JAN… (RTTNews)
20.10.22	Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate (PR Newswire)
17.10.22	Pre-market Movers: INPX, GEHI, HAPP, MPTI, ADEA… (RTTNews)
12.10.22	Pre-market Movers: SLS, CANG, HKD, GATO, CCJ… (RTTNews)
10.10.22	Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.44	1.57 %	K V
Kuehne+Nagel Int	210.00	0.57 %	K V
Givaudan	3’907.00	0.15 %	K V
Zurich Insur Gr	551.80	-0.04 %	K V
Logitech Intl	72.10	-0.14 %	K V
ABB	49.49	-0.94 %	K V
Nestle	75.24	-0.95 %	K V
Sika	228.90	-0.99 %	K V
UBS Group	28.02	-1.16 %	K V
Roche Hldg G	249.70	-1.50 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Immunic Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten